Neurotransmitters are chemical substances, synthesized and released by nerve cells, or glandular hormones that excite or inhibit other nerve, muscle, or gland cells. Known neurotransmitters include acetylcholine, aspartic acid, catecholamines, cholecystokinin, endorphins, gamma aminobutyric acid, glutamic acid, glycine, histamine, neurotensin, serotonin, and substance P.
Project 4: Neurogenomic model for dopamine transporter regulation--National Institute of Diabetes and Digestive and Kidney Diseases (2000-2005)
Randy Blakely, Ph.D., Principal Investigator
Regulation of serotonin transporters--National Institute on Drug Abuse (1994-2004)
Randy Blakely, Ph.D., Principal Investigator
Mechanisms of CaM kinase II signal transduction--National Institute of Mental Health (2001-2006)
Roger Colbran, Ph.D., Principal Investigator
Targeting of brain protein phosphatase 1--National Institute of Neurological Disorders and Stroke (1998-2003)
Roger Colbran, Ph.D., Principal Investigator
Project 2: Modulation of dendritic CaMKII by dopamine--National Institute of Neurological Disorders and Stroke (2002-2007)
Roger Colbran, Ph.D., Principal Investigator
Molecular physiology of brain cation-chloride cotransporters--National Institute of Neurological Disorders and Stroke (1999-2004)
Eric Delpire, Ph.D., Principal Investigator
Dopamine system interactions and schizophrenia--National Institute of Mental Health (1998-2004)
Ariel Deutch, Ph.D., Principal Investigator
Monoaminergic regulation of GABA and schizophrenia--National Institute of Mental Health (1997-2005)
Ariel Deutch, Ph.D., Principal Investigator
Project 1: Dopamine and dendritic spines--National Institute of Neurological Disorders and Stroke (2002-2007)
Ariel Deutch, Ph.D., Principal Investigator
Post-transcriptional regulation of serotonin receptors--National Institute of Neurological Disorders and Stroke (1997-2007)
Ronald Emeson, Ph.D., Principal Investigator, Elaine Sanders-Bush, Ph.D.
The major goals of these studies are to evaluate the signaling properties of distinct 5-HT2c receptor isoforms generated by RNA editing, to generate mutant strains of mice and to characterize the physiological consequences resulting from expression of a single, edited 5-HT2c R isoform, and to examine the role of 5-HT2c receptor editing and signaling in cellular transformation and tumorigenesis.
In vivo relevance of alpha2AR trafficking itineraries--National Heart, Lung, and Blood Institute (1995-2004)
Lee Limbird, Ph.D., Principal Investigator
Mechanisms for GPCR trafficking in polarized cells--National Institute of Diabetes and Digestive and Kidney Diseases (1993-2004)
Lee Limbird, Ph.D., Principal Investigator
Proteomic analysis of eukaryotic protein synthesis--National Institute of General Medical Sciences (2002-2007)
Andrew Link, Ph.D., Principal Investigator
Characterization of central serotonin receptors--National Institute of Mental Health (1980-2005)
Elaine Sanders-Bush, Ph.D., Principal Investigator, Ronald Emeson, Ph.D., and Randy Smith, Ph.D.
This project focuses on the regulation of serotonin receptor function in vitro and in vivo, using molecular, cellular, and behavioral strategies.
Hallucinogens and serotonin signal transduction--National Institute on Drug Abuse (1988-2003)
Elaine Sanders-Bush, Ph.D., Principal Investigator, Randy Smith, Ph.D.
Ethanol inhibition of NMDA receptor mediated responses--National Institute of Alcohol Abuse and Alcoholism (1991-2005)
Danny Winder, Ph.D., Principal Investigator, Roger Colbran, Ph.D.
Regulation of LTP by Gi linked receptors--National Institute of Drug Abuse (2001-2006)
Danny Winder, Ph.D., Principal Investigator
National Institute on
Drug Abuse
National Institute of
Mental Health
National Institute of
Neurological Disorders and Strokes